Aptabio Therapeutics (293780) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Aptabio Therapeutics (293780) reported revenue of 3.7 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20253.7 billion KRW-15.8 billion KRW-16.3 billion KRW[source]
20243.4 billion KRW-18.9 billion KRW-29.4 billion KRW[source]
2023324 million KRW-16.4 billion KRW-12.1 billion KRW[source]
202248 million KRW-9.5 billion KRW-10.6 billion KRW[source]
2021224 million KRW-11.4 billion KRW-10.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202558.9 billion KRW12.9 billion KRW46.1 billion KRW[source]
202477.2 billion KRW23.3 billion KRW53.9 billion KRW[source]
202392.5 billion KRW31.2 billion KRW61.4 billion KRW[source]
202256.1 billion KRW3.7 billion KRW52.4 billion KRW[source]
202164.9 billion KRW3.2 billion KRW61.7 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice